CARsgen unveils ASH 2026 data abstracts for CD19/20 and GPRC5D CAR-T programs

Bulletin Express11-05

CARsgen Therapeutics Holdings Limited (CARsgen) has released research abstracts for two chimeric antigen receptor T-cell (CAR-T) candidates—CT1190B and CT071—ahead of the 68th Annual Meeting of the American Society of Hematology (ASH) in 2026. Both datasets will be presented as posters at the conference. A separate update on CT0596 will follow in December 2026.

CT1190B • Modality: Allogeneic CAR-T targeting CD19/CD20 • Indication: Relapsed/refractory large B-cell lymphoma • Development status: Registrational Phase I trial under way leveraging the THANK-u Plus® platform

CT071 • Modality: Autologous CAR-T targeting GPRC5D • Indications: Relapsed/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM) • Trials: – Investigator-initiated trial NCT05838131 for R/R MM or plasma cell leukemia – Investigator-initiated trial NCT06407947 for HR-NDMM • Platform: CARcelerate®

CT0596 (Upcoming Disclosure) • Modality: Allogeneic CAR-T targeting BCMA • Indications: R/R MM and primary plasma cell leukemia • Development status: Registrational Phase I trial ongoing; prior IITs indicated favorable tolerability and encouraging efficacy signals • Additional exploration: Planned studies in further plasma cell malignancies and autoimmune disorders driven by autoreactive plasma cells

Corporate Snapshot CARsgen is a Hong Kong-listed biopharmaceutical company specializing in next-generation CAR-T therapies for hematologic malignancies, solid tumors and autoimmune diseases. The firm operates an end-to-end platform encompassing target discovery, preclinical research, clinical development and commercial-scale manufacturing.

Regulatory Note The company cautions that clinical development outcomes for CT1190B, CT071 and CT0596 remain uncertain. Shareholders and prospective investors are advised to exercise caution when dealing in CARsgen shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment